Project-004

项目-004

基本信息

批准号：
10705953
负责人：
MADHAV V DHODAPKAR
金额：
$ 19.95万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-30 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10705953
关键词：
2019-nCoV Acute Address African American Antibody Formation Antibody Response Antitumor Response Autoimmune Autoimmune Diseases Autoimmunity B lymphoid malignancy B-Lymphocytes Biology COVID-19 COVID-19 severity COVID-19 vaccination COVID-19 vaccine Cancer Patient Cells Clinical Data Set Defect Development Disease Ensure Enzyme-Linked Immunosorbent Assay Epigenetic Process Equilibrium Future Generations Genetic Transcription Hematologic Neoplasms Heterogeneity Immune Immune response Immune system Immunity Immunologic Monitoring Immunologics Immunology Impairment Inflammation Inflammatory Innate Immune Response Longevity Malignant - descriptor Malignant Neoplasms Malignant neoplasm of lung Measures Mediating Memory B-Lymphocyte Minority Molecular Monitor Nature Non-Small-Cell Lung Carcinoma Outcome Paresis Pathogenesis Pathogenicity Pathway interactions Patients Plasma Cells Population Population Programs Regulation Research Research Personnel Risk Role SARS-CoV-2 immunity SARS-CoV-2 infection Sampling Scientist Systemic Lupus Erythematosus T cell response T-Lymphocyte Target Populations Technology Time Tumor Antigens University Hospitals Vaccines Viral Virus Virus Diseases Work adaptive immune response antiviral immunity cancer therapy coronavirus disease density experience high risk immune checkpoint blockade immunopathology immunoregulation infection rate inflammatory milieu insight interest long term memory mortality multidisciplinary neutralizing antibody pathogenic autoantibodies patient population post SARS-CoV-2 infection programs prospective recruit repository response serosurveillance success translational study tumor

项目摘要

Abstract: The Emory U54 SeroNET U54 program is a multidisciplinary program that brings together experienced team of investigators to tackle fundamental issues relating to immunity to SARS CoV-2, particular in patients with cancer and autoimmunity. The team has a long track record of prior work in basic and translational studies in the setting of viral infections, vaccines and cancer. The program consists of 3 interacting projects and two essential cores in addition to the administrative core. Studies in project 1 (led by Sanz) will study the biology of SARS CoV-2 specific effector B cell responses in patients with autoimmunity, with a particular focus on extrafollicular B cell pathway. Studies in project 2 (led by Sekaly and Wrammert) will study the role of inflammatory milieu in regulating antiviral immunity and in the development of long term memory responses. Studies in project 3 (led by Dhodapkar and Ahmed) will focus on studying the impact of specific cancer therapies, in particular B/plasma cell depleting therapies in patients with B/plasma cell malignancies, and immune checkpoint blockade in patients with lung cancer. These studies will also set the stage for studying immune responses to future SARS CoV-2 vaccines in patients with autoimmunity as well as cancer patients. The programs are supported by active cores (led by Roback and Neish) which have experience with monitoring immunity to SARS CoV-2. Together, this program will not only provide basic insights into immune-pathogenesis of COVID, but also provide the consortium with access to unique patient populations at higher risk of COVID-related mortality.

抽象的： Emory U54 Seronet U54程序是一个多学科程序，可以融合经验丰富的调查人员团队，以解决与免疫有关的基本问题 SARS COV-2，尤其是癌症和自身免疫患者。团队有很长的在病毒感染的基础和翻译研究中的先前工作的记录，疫苗和癌症。该计划由3个互动项目和两个必不可少的除了行政核心外，核心。项目1的研究（由SANZ领导）将研究 SARS COV-2特异性效应子B细胞反应的生物学自身免疫性，特别关注流体外B细胞途径。项目研究 2（由Sekaly和Wrammert领导）将研究炎症环境在调节中的作用抗病毒免疫和长期记忆反应的发展。研究项目3（由Dhodapkar和Ahmed领导）将专注于研究特定的影响癌症疗法，特别是B/等离子体患者的B/等离子体细胞耗尽疗法肺癌患者的细胞恶性肿瘤和免疫检查点阻滞。这些研究还将为研究对未来SARS COV-2的免疫反应奠定阶段自身免疫性和癌症患者的疫苗。程序是在有活跃的核心（由Roback和Neish的领导）的支持下，具有经验监测对SARS COV-2的免疫力。在一起，该程序不仅将提供基本洞悉共vid的免疫致病发生，但也提供了财团访问具有相互关联死亡率风险较高的独特患者人群。